The Europe Analgesics Market would witness market growth of 6.2% CAGR during the forecast period (2022-2028).
The most often used OTC analgesic is paracetamol. It has analgesic properties similar to aspirin and ibuprofen. There are no anti-inflammatory properties in it. Within the central nervous system, paracetamol suppresses prostaglandin production. It is the most commonly used analgesic for pain relief. The anticoagulant impact of coumarins may be enhanced by long-term usage of paracetamol. Hypersensitivity and rare occurrences of blood dyscrasias are common adverse effects of paracetamol, including agranulocytosis and thrombocytopenia. Another typical OTC analgesic is aspirin. Analgesic, antiplatelet, antipyretic, and anti-inflammatory are properties of aspirin. Aspirin's analgesic action is due to the suppression of cyclooxygenase. Epigastric discomfort, nausea and vomiting, gastrointestinal ulceration, hypersensitivity, and arthritis are all antagonistic effects of aspirin.
The healthcare sector of this region is significantly robust, which is allowing major market players to increase their efforts and investments in the advancement of the regional healthcare infrastructure. The European Commission announced the introduction of the European Research Area (ERA) corona platform in May 2020, which would give information on coronavirus research and innovation. In addition, the European Medicines Agency has recommended that mild COVID-19 symptoms be treated with non-steroidal anti-inflammatories (NSAIDs), such as paracetamol and ibuprofen, in the lowest dose form. Furthermore, because elderly people are more vulnerable to infection due to weakening immune systems and the lack of a vaccine or therapy, the number of older persons infected with coronavirus is high. The utilization of analgesics are increasing in the region in order to treat the side-effects of this.
The Germany market dominated the Europe Analgesics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,880.8 Million by 2028. The UK market is poised to grow at a CAGR of 5.3% during (2022 - 2028). Additionally, The France market would witness a CAGR of 7% during (2022 - 2028).
Based on Type, the market is segmented into Non-opioids and Opioids. Based on Route of Administration, the market is segmented into Oral, Transdermal, Intravenous, Topical, and Rectal. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Analgesics Market will Hit $42.6 Billion by 2028, at a CAGR of 6.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Reckitt Benckiser Group PLC, Abbott Laboratories, Johnson & Johnson, Bayer AG, Endo International PLC, GlaxoSmithKline PLC, Pfizer, Inc., Sanofi S.A., and Eli Lilly And Company.
By Type
By Route of Administration
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
